1. Knowledge Base
  2. Clinical Resources
  3. Pharmacist Disease State Guides

Depression

Disease State Overview

Depression is a condition characterized by low mood, a lack of positive thoughts, and a loss of interest in previously pleasurable activities that lasts longer than two weeks.  

 

Treatment of depression is based on four phases as outlined below. Treatment goals include achieving remission of depression symptoms and restoring normal functioning and quality of life. Once remission is achieved, goals of treatment include prevention of relapse, optimization of treatment modalities, and minimization of adverse effects. 

 

Depression Treatment Phases 

Risk of Condition 

If left untreated, depression may cause serious, long-lasting symptoms and often disrupts a person’s ability to perform routine tasks. Untreated depression can increase a patient’s risk of developing other chronic health conditions and can also increase risk of death by suicide.  

 

Medication 

Role of Medication 

The American College of Physicians recommends patient start on either pharmacologic therapy or cognitive behavioral therapy. Choice of therapy should be based on multiple factors including depression severity, depression features, medication side effect profile, medication tolerability, history of prior medication treatment, insurance coverage, patient preference, patient’s age, comorbid conditions, and concurrent medications.  

 

Pharmacologic and non-pharmacologic treatment options as recommended by the American Psychiatric Association (APA) are outlined below. Medications should be titrated to maximally tolerated dose prior to switching or augmenting therapy. 

 

Pharmacologic Management of Major Depressive Disorder 

Pharmacological Therapy 

Drug Class 

Medications 

Class Side Effects 

Selective serotonin reuptake inhibitor (SSRI) 

citalopram 

escitalopram 

fluoxetine 

paroxetine 

sertraline  

fluvoxamine+  

CNS: insomnia, headache 

GI: nausea/vomiting, weight gain, dry mouth 

Other: hyponatremia/SIADH, sexual dysfunction, bleeding risk, QT prolongation* 

 

*increased risk with citalopram doses > 40mg  

Selective serotonin-norepinephrine reuptake inhibitor (SNRI) 

desvenlafaxine 

duloxetine 

levomilnacipran (Fetzima) 

milnacipran 

venlafaxine 

CNS: insomnia, headache 

GI: nausea/vomiting, weight gain, dry mouth 

Cardiac: hypertension, tachycardia/palpitations 

Other: hyponatremia/SIADH, sexual dysfunction  

Alpha-2 antagonist  

Other Classifications:  

  1. Tetracyclic (TeTCA)   
  1. Norepinephrine-serotonin modulator 
  1. Noradrenergic and specific serotonergic (NaSSAs) 

mirtazapine 

CNS: sedation 

GI: nausea, vomiting, constipation, weight gain 

Cardiac: increased cholesterol  

Other: dry mouth  

Dopamine norepinephrine reuptake inhibitor (DNRIs) 

bupropion 

CNS: insomnia, activation/anxiety, headache 

GI: nausea, weight loss, dry mouth 

Cardiac: hypertension, tachyarrhythmia, 

Other: seizures, diaphoresis 

Tricyclic antidepressants (TCAs)  

Secondary Amine  

amoxapine 

desipramine 

nortriptyline 

protriptyline  

 

Tertiary Amine  

amitriptyline 

clomipramine+ 

doxepin 

imipramine 

trimipramine 

CNS: sedation* 

GI: weight gain 

Anticholinergic: dry mouth, urinary retention, dry mouth, constipation, cognitive impairment 

Cardiac: QTc prolongation, arrhythmias, orthostatic hypotension* 

Other: sexual dysfunction, seizures  

 

*less with secondary amine vs. tertiary amine TCAs 

Tetracyclic antidepressant (TeTCAs) 

maprotiline  

CNS: sedation 

GI: weight gain 

Anticholinergic: dry mouth, urinary retention, dry mouth, constipation, cognitive impairment 

Other: blurred vision/visual disturbance   

Serotonin Modulators 

Selective Serotonin Reuptake Inhibitor/5-HT1A Receptor Partial Agonist 

vilazodone 

CNS: insomnia 

GI: nausea, vomiting, diarrhea  

Other: sexual dysfunction* 

 

*potentially less than other agents  

Serotonin Modulators 

Selective Serotonin Reuptake Inhibitor/Serotonin 5-HT1A Receptor Agonist/Serotonin 5-HT3 Receptor Antagonist 

vortioxetine 

CNS: insomnia 

GI: nausea, vomiting diarrhea 

Other: sexual dysfunction* 

 

*potentially less than other agents 

Serotonin Modulators 

Serotonin Reuptake Inhibitor/Antagonist 

trazodone 

nefazodone  

 

CNS: sedation 

GI: nausea  

Cardiac: orthostatic hypotension 

Other: priapism* 

 

*rare but serious; trazodone only 

Monoamine oxidase inhibitor (MAOIs) 

 

 

isocarboxazide 

phenelzine 

selegiline 

traylcypromine 

CNS: insomnia, hypersomnia 

GI: weight gain 

Anticholinergic: dry mouth 

Cardiac: orthostatic hypotension, decreased heart rate,  
peripheral edema, hypertensive crisis 

Other: sexual dysfunction 

Note: MAOIs generally restricted to patients who do not respond to other therapies 

+ FDA indicated for OCD only 

 

Non-pharmacological Therapy 

Psychotherapy 

Transcranial magnetic stimulation (TMS) 

Electroconvulsive therapy (ECT) 

Light therapy 

 

Adherence 

Medication adherence is an essential component of treating depression because full response to pharmacotherapy typically occurs within the first 4–8 weeks of initial treatment. Discuss barriers to adherence and provide appropriate solutions. You may use the DRAW tool located in the Worksheets & Forms category of this Knowledge Base.

 

Educate the patient about the risks associated with sudden discontinuation of antidepressants. Symptoms may include changes in mood, irritability, anxiety, insomnia, headache, GI upset, or electric shock sensation. 

 

Administration 

Most antidepressants may be taken at any time of day. If the medication makes the patient feel stimulated or drowsy, they may need to change the time of day they take the medication.  

 

Monitoring 

Frequent follow-up should be scheduled with the patient’s prescriber to monitor response to treatment, adherence to the treatment plan, and suicide risk. Close observation and communication with the prescriber should be recommended to both the patient and their family.  

 

The Patient Health Questionnaire (PHQ-9) is a common tool used to monitor both the severity of depression and response to treatment. Monitoring should also include screening for other mental disorders or chronic conditions.  

 

Lifestyle Education 

Lifestyle modifications can positively impact depression management. Points to discuss with patients may include the following: 

  1. Advise patient to follow a healthy diet 
  1. Encourage patient to be physical activity as physical activity has been shown to have significant benefits for mental health 
  1. Recommend limited alcohol consumption because alcohol is a depressant itself 
  1. Educate the patient about the importance of sleep hygiene because poor sleep has a strong, negative impact on mood 

 

Additional Points 

Patients with depression should be counseled on the following points related to pharmacologic treatment: 

  1. All antidepressants carry a black box warning of increased risk of suicidality in children, adolescents, and young adults ≤ 24 years of age. Advise patients who have thoughts about hurting themselves to go to the emergency room, contact their provider or call the National Suicide Prevention Hotline at 1-800-273-8255 or visit www.suicidepreventionlifeline.org
  1. Some medication side effects may resolve within the first few weeks of treatment initiation, so it is important to continue therapy if side effects are tolerable.  
  1. The signs and symptoms of serotonin syndrome include mental status change, autonomic hyperactivity, and neuromuscular abnormalities. Patients should seek immediate medical attention should they occur. 

 

 

 

Resources 

  1. American Psychological Association (APA). Practice Guideline for the Treatment of Patients with Major Depressive Disorder (3rd edition). May 2011. American Psychiatric Association.  
    https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf 
  2. American Psychological Association (APA). Treating Major Depressive Disorder: A Quick Reference Guide.  
    https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd-guide.pdf 
  3. Chapman DP, Perry GS, Strine TW. The vital link between chronic disease and depressive disorders. Prev Chronic Dis [serial online] 2005;2(1).  
    https://pubmed.ncbi.nlm.nih.gov/15670467/ 
  4. Qaseem A et al. Nonpharmacologic Versus Pharmacologic Treatment of Adult Patients with Major Depressive Disorder: A Clinical Practice Guideline From the American College of Physicians. Annals of Internal Medicine.  
    https://www.acpjournals.org/doi/10.7326/M15-2570 
  5. Trangle M, Gursky J, Haight R, Hardwig J, Hinnenkamp T, Kessler D, Mack N, Myszkowski M. Institute for Clinical Systems Improvement. Adult Depression in Primary Care.  
    https://www.icsi.org/wp-content/uploads/2019/01/Depr.pdf